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Fluorinated organic compounds (FOCs), such
as perﬂuorooctane sulfonate (PFOS), perﬂuoro-
octanoate (PFOA), and perfluorooctane sul-
fonylamide (PFOSA), are stable chemicals
with a wide range of industrial and consumer
applications (Renner 2001). Recent reports
have indicated the presence of these environ-
mental contaminants in wildlife and river
water (Giesy and Kannan 2001; Kannan et al.
2001; Saito et al. 2003; Taniyasu et al. 2003).
FOCs have been manufactured for > 50 years
and are used as refrigerants, surfactants, and
polymers and as components of paper coat-
ings, ﬁre retardants, adhesives, cosmetics, and
insecticides (Key et al. 1997).
In the United States, PFOS is a stable FOC
with many industrial applications. The amount
of PFOS used in consumer application totals
5.6 million lb [U.S. Environmental Protection
Agency (EPA) 2000]. These ﬁndings prompted
the major manufacturer of PFOS in the United
States, 3M Company, to halt production in the
end of 2002 (Renner 2001). However, PFOS is
still available on the Japanese market. A recent
evaluation of PFOS toxicity in green algae
revealed that the no observable effect concen-
tration (NOEC) ranges from 5.3 to 8.2 mg/L
(Boudreau et al. 2003). In addition, PFOS is
well absorbed but poorly metabolized and
excreted, and it has a long half-life (200 days)
in monkeys (Seacat et al. 2002). On the other
hand, the potential toxicity of PFOS in general
is not well characterized, and even less known
are the mechanisms underlying its toxic effects.
Hepatic toxicity and altered thyroid hormone
levels have been found in monkeys and rodents
(Luebker et al. 2002; Seacat et al. 2002, 2003).
PFOS interferes with mitochondrial bioener-
getics, and cell–cell communication has been
implicated as a potential mechanism of toxicity
(Hu et al. 2002, 2003). Recently, the neuro-
endocrine effects of PFOS were reported in the
rat (Austin et al. 2003). In addition, maternal,
developmental, and postnatal toxicities of
PFOS were reported in the rat and mouse (Lau
et al. 2003; Thibodeaux et al. 2003), showing
that exposure to PFOS of pregnant rats and
mice leads to signiﬁcant physiologic alterations
and that additional investigations are required
to elucidate the pathophysiologic mechanisms.
PFOA is widely used in the production of
chemicals and in aircraft and electronic prod-
ucts manufacturing. PFOA does not appear
to be biomagniﬁed in animals. However, it is
a persistent pollutant, and low concentrations
are detected in human blood, according to a
risk assessment study (Renner 2003). In the
same manner as PFOA, risk assessment of
PFOSA is required for evaluating exposure
levels and effects.
Because of the ubiquity of FOCs and
their potential role in increasing the risk of
neuroendocrine and reproductive dysfunc-
tion, human exposure assessment studies
are urgently needed. A quantitative analysis
of four FOCs in 65 human serum samples
collected from several biologic supply com-
panies in the United States detected PFOS
(6.7–81.5 ng/mL), PFOA [limit of quantita-
tion (LOQ), 35.2 ng/mL], and PFOSA
(LOQ, 2.2 ng/mL) (Hansen et al. 2001). A
study of human exposure to FOCs found
that mean serum PFOS concentration was
17.7 ng/mL in 24 donors (Olsen et al. 2003b).
In Japan, there is only one report of exposure
in humans (Taniyasu et al. 2003), indicating
that PFOS concentrations range from 2.4 to
14 ng/mL. Recently, a rapid and sensitive
method for measuring 15 FOCs in human
breast milk and serum has been developed
(Calafat et al. 2003). The study of human
exposure to FOCs requires information about
the concentration of these toxicants in a non-
occupationally exposed population. However,
to our knowledge, there is no study of FOCs in
human maternal and cord blood samples for
fetal risk assessment. Human fetal and maternal
exposure assessment studies are urgently needed
because maternal and developmental toxicities
of PFOS have been indicated (Lau et al. 2003;
Thibodeaux et al. 2003).
The aim of the present study was to
determine human cord and maternal serum
concentrations of PFOS, PFOA, and PFOSA
for fetal risk assessment. Although based on
only a small sample set, our ﬁndings indicate
the levels of FOCs to which Japanese women
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Fluorinated organic compounds (FOCs), such as perfluorooctane sulfonate (PFOS), perfluoro-
octanoate (PFOA), and perﬂuorooctane sulfonylamide (PFOSA), are widely used in the manufacture
of plastic, electronics, textile, and construction material in the apparel, leather, and upholstery indus-
tries. FOCs have been detected in human blood samples. Studies have indicated that FOCs may be
detrimental to rodent development possibly by affecting thyroid hormone levels. In the present study,
we determined the concentrations of FOCs in maternal and cord blood samples. Pregnant women
17–37 years of age were enrolled as subjects. FOCs in 15 pairs of maternal and cord blood samples
were analyzed by liquid chromatography–electrospray mass spectrometry coupled with online extrac-
tion. The limits of quantiﬁcation of PFOS, PFOA, and PFOSA in human plasma or serum were 0.5,
0.5, and 1.0 ng/mL, respectively. The method enables the precise determination of FOCs and can be
applied to the detection of FOCs in human blood samples for monitoring human exposure. PFOS
concentrations in maternal samples ranged from 4.9 to 17.6 ng/mL, whereas those in fetal samples
ranged from 1.6 to 5.3 ng/mL. In contrast, PFOSA was not detected in fetal or maternal samples,
whereas PFOA was detected only in maternal samples (range, < 0.5 to 2.3 ng/mL, 4 of 15). Our
results revealed a high correlation between PFOS concentrations in maternal and cord blood
(r2 = 0.876). However, we did not ﬁnd any signiﬁcant correlations between PFOS concentration in
maternal and cord blood samples and age bracket, birth weight, or levels of thyroid-stimulating hor-
mone or free thyroxine. Our study revealed that human fetuses in Japan may be exposed to relatively
high levels of FOCs. Further investigation is required to determine the postnatal effects of fetal expo-
sure to FOCs. Key words: cord blood, fluorinated organic compounds, human, PFOA, PFOS,
PFOSA, pregnancy. Environ Health Perspect 112:1204–1207 (2004). doi:10.1289/ehp.6864 avail-
able via http://dx.doi.org/ [Online 13 April 2004]are exposed. We developed an easy, reliable,
and high-throughput analytical method that
uses liquid chromatography–electrospray mass
spectrometry (LC-MS) coupled with online
extraction to measure speciﬁc FOCs in human
plasma and serum samples. This method
enables the precise determination of standards
in human blood samples and can be applied
to the detection of PFOS, PFOA, and PFOSA
in human blood samples for monitoring
human exposure.
Materials and Methods
Clinical materials. We recruited subjects
between February and July 2003 at Sapporo
Toho Hospitals in Hokkaido, Japan. This
study was conducted with all the subjects’
written informed consent and was approved
by the institutional ethical board for epidemi-
ologic studies at the Hokkaido University
Graduate School of Medicine. The data of
physical and biologic examinations, laboratory
tests, and questionnaires were recorded by
the Department of Public Heath, Hokkaido
University Graduate School of Medicine.
Blood was sampled from pregnant women
(n = 15; Table 1) between gestation weeks 38
and 41 (mean ± SD, 39.7 ± 1.05). Cord blood
samples were collected immediately after birth
by using standard procedure, which included
careful cleansing of the cord and strict punc-
ture of the umbilical vein to avoid maternal
contamination. Body mass index (BMI) was
calculated from the information given in
Table 1 (height, prepregnancy weight, and
weight at delivery).
FOC analysis. PFOS [molecular weight
(MW), 538.23; 98% purity], PFOA (MW,
414.07; > 90%), and PFOSA (MW, 199.14;
97%) were purchased from Wako Pure
Chemical Inc. (Osaka, Japan), Fluka Chemie
AG (Buchs, Switzerland), and ABCR GmbH
& Co. (Im Schlehert, Germany). The internal
standard (perfluorodecanoic acid) was
purchased from Lancaster Company, Inc.
(Morecambe, UK). Other reagents and sol-
vents were of HPLC grade and were pur-
chased from Wako Pure Chemical Inc.
(Osaka, Japan). The distilled water purifica-
tion system was Milli-Q gradient A 10 with an
EDS polisher (Millipore, Bedford, MA, USA).
LC-MS with electrospray ionization was
performed using an Agilent 1100 MSD-SL
system (Agilent Technologies, Palo Alto, CA,
USA). The working conditions were as fol-
lows: The drying nitrogen gas temperature was
set at 350°C and was introduced into the cap-
illary region at a flow rate of 12 L/min; the
capillary was held at a potential of 3,500 V rel-
ative to the counter electrode in the negative-
ion mode for all compounds. The fragmenter
voltages were 220 V for PFOS, 130 V for
PFOA, and 170 V for PFOSA during the
chromatographic run. The direct injection
volume was 30 µL. The column used was
Inertsil C8–3 (2.1 × 100 mm, 5 µm; GL
Sciences Inc., Tokyo, Japan) with a Mightysil
RP-18 GP precolumn (2.0 × 5 mm, 5 µm;
Kanto Chemical Inc., Osaka, Japan).
The column-switching LC-MS coupled
with an on-line extraction system consisted of
this LC-MS combined with an LC pump
(Shimadzu LC-10 ADvp pump; Shimadzu,
Kyoto, Japan) and Oasis HLB extraction
column (20 × 2.1 mm, 25 µm; Waters Co.,
Milford, MA, USA). After a blood sample
was injected by an autosampler, it was loaded
onto the extraction column by flowing
water/methanol (90/10, vol/vol) at a rate of
1.0 mL/min using a Shimadzu pump for
5 min. After on-line extraction for 5 min,
the position of the switching valve was
changed. This configuration connected the
back-ﬂashing extraction column to the analyt-
ical column and the MS detector in the ﬂow
path of the Agilent pump. After 20 min, the
switching valve was returned to its original
position. The run time for the assay of the
sample mixture was 30 min. Gradient mobile
phase of 1.0 mM ammonium acetate in
water/acetonitrile (vol/vol) was used at a ﬂow
rate of 0.2 mL/min (5–15 min using a linear
increase from 65 to 85% acetonitrile solution
and holding at 85%).
In the quantitative procedure, standard
solutions of PFOS, PFOA, and PFOSA were
prepared in aqueous solution to cover the cal-
ibration range. Quantitative analysis was per-
formed in the single ion monitoring mode to
maximize sensitivity. PFOS, PFOA, and
PFOSA concentrations in each sample were
calculated relative to the internal standard
added to the sample before direct analysis.
Calibration curves of PFOS, PFOA, and
PFOSA were performed daily for all samples
with internal standard. We added 0.3 mL of
sample to 0.3 mL of internal standard solu-
tion. The mixed sample was centrifuged at
3,000 × g for 10 min. The top clear layer was
removed to the glass tube. This sample solu-
tion was ﬁltered. This solution was analyzed
by column-switching LC-MS. We analyzed
quality-control materials (spiked samples in
25 ng/mL of PFOS) with each batch of
samples on separated days. In the result, this
material did not deviate from the 99% conﬁ-
dence interval (CI) (in this case, 99% CI,
24.17–25.53).
The method was developed previously.
The compounds were separated by reverse-
phase LC with a C8 column and detected by
MS in the selected ion monitoring mode.
When working in the selected ion monitoring
mode, the m/z ions for PFOS, PFOA, and
PFOSA were [M–K]– 499, [M–COOH]–
369, and [M–H]– 498. In addition, the m/z
ion of the internal standard was designated as
[M–COOH]– 469 in the negative ion mode.
The analysis of trace levels of PFOS,
PFOA, and PFOSA in biologic samples is
complicated by contamination, particularly by
leaching from Teﬂon plastic. Thus, care must
be taken to control contamination during
experiments and, where possible, to eliminate
the contamination. Investigations of PFOS,
PFOA, and PFOSA contamination of the
Milli-Q water system, the plastic tube, and the
LC system produced negative results (below
the limit of detection). We investigated
whether the recoveries of PFOS, PFOA, and
PFOSA (10 and 100 ng/mL) in the samples
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Table 1. Characteristics of mothers and infants
(n = 15).
Characteristics Median (range)
Maternal age (years) 28.4 (17–37)
Gestation (weeks) 39.7 (38–41)
Maternal height (cm) 157.2 (148–168)
Maternal prepregnancy weight (kg) 50.3 (40–61)
Maternal weight at delivery (kg) 60.4 (49.1–72)
Infants
Male [n (%)] 8 (53.3)
Female [n (%)] 7 (46.7)
Birth weight (g) 3125.7 (2,579–4,162)
Table 2. Concentrations (ng/mL) of FOC congeners (PFOS, PFOA, and PFOSA) in maternal and cord blood
samples (n = 15).
Maternal Fetal
Sample no. PFOS PFOA PFOSA PFOS PFOA PFOSA
1 10.4 0.7 ND 3.9 ND ND
2 17.6 2.3 ND 5.3 ND ND
3 9.5 ND ND 3.9 ND ND
4 7.9 ND ND 2.4 ND ND
5 12.8 ND ND 4.7 ND ND
6 5.4 ND ND 1.6 ND ND
7 7.9 ND ND 2.3 ND ND
8 9.5 0.5 ND 3.0 ND ND
9 7.9 ND ND 2.4 ND ND
10 5.8 ND ND 2.1 ND ND
11 9.9 ND ND 2.8 ND ND
12 8.1 ND ND 2.5 ND ND
13 4.9 ND ND 1.7 ND ND
14 8.3 ND ND 2.8 ND ND
15 6.9 ND ND 1.6 ND ND
ND, not detected: PFOS < 0.5 ng/mL; PFOA < 0.5 ng/mL; PFOSA < 1.0 ng/mL.could be determined by this method. The
average recoveries of PFOS, PFOA, and
PFOSA ranged from 82.2 to 98.7%, with rela-
tive standard deviation < 5.2%. We used this
method to assess FOC levels in human blood
samples to obtain a reference range.
Thyroid hormone estimation. Thyroid-
stimulating hormone (TSH) and free thyrox-
ine (T4) levels of newborns were measured in
Sapporo City Institute of Public Health.
Blood specimens on ﬁlter paper were collected
from infants between 4 and 7 days of age.
TSH and free T4 were determined in single
0.3-cm disks punched from the same filter-
paper blood. TSH and free T4 were measured
using enzyme-linked immunosorbent assay
(TSH: Enzaplate N-TSH, Bayer Co., Tokyo,
Japan; free T4: Enzaplate N-FT4, Bayer).
Detection limits were for TSH, 0.5 µIU/mL,
and for free T4, 0.20 ng/dL, respectively.
Results
We were able to realize a low LOQ and rapid
analysis using the developed column-switching
LC-MS coupled with on-line extraction
method. The calculated LOQs when the signal-
to-noise ratio was 10 were 0.5 for PFOS,
0.5 for PFOA, and 1.0 ng/mL for PFOSA in
human serum samples.
We analyzed 15 pairs of maternal and cord
serum samples for PFOS, PFOA, and PFOSA
by this method. In the results (Table 2), the
percentage detection of PFOS, PFOA, and
PFOSA in the maternal and cord samples was
100% (30 of 30), 10% (3 of 30), and 0% (0 of
30), respectively. The concentrations of PFOS
in maternal serum samples ranged from 4.9 to
17.6 ng/mL, whereas those in cord samples
ranged from 1.6 to 5.3 ng/mL. The PFOS
concentrations in maternal and cord blood
samples were highly correlated (r2 = 0.876)
(Figure 1). The average maternal age was
28.4 years, with a range of 17–37 years. In
addition, the average BMIs based on prepreg-
nancy weight and on weight at delivery were
20.3 and 24.4, respectively. PFOS concentra-
tion was not correlated with these parameters
(Figure 2). On the other hand, Figure 3
shows no apparent correlation between cord
PFOS concentration and sex and weight
at birth. In addition, Figure 4 shows no
apparent correlation between cord PFOS con-
centration and thyroid hormone factors such
as TSH and free T4.
Discussion
To the best of our knowledge, this is the ﬁrst
report of PFOS and its related compounds in
pregnant Japanese women and fetal cord
blood. The issue of the bioavailability of
PFOS in human, particularly in pregnant
women and their cord blood, is controversial.
A study of female human exposure levels of
PFOS concentration found that levels in the
United States are approximately twice those
in Japan (Olsen et al. 2003b; Taniyasu et al.
2003). In contrast, PFOS concentrations in
cord blood samples have not been reported so
far. Therefore, we cannot compare our cord
blood PFOS exposure levels with other data.
However, a study of exposure to PFOS during
pregnancy in the rat and mouse indicated that
the amount of accumulated PFOS is propor-
tional to the treatment dosage and the levels
detected in fetal liver; in terms of concentra-
tion, the fetal liver level appears to contain
approximately half as much PFOS as its
maternal counterpart (Thibodeaux et al.
2003). Based on our study, the mean ratio of
PFOS concentration in maternal blood to that
in cord blood is 0.32 (range, 0.23–0.41). The
studies of PFOS exposure during pregnancy
in the rat and mouse (Lau et al. 2003;
Thibodeaux et al. 2003) support our ﬁndings
that PFOS accumulation can be measured in
humans and that there is a high correlation
between PFOS concentrations in maternal
and cord blood.
On the other hand, PFOA was detected in
a small number of maternal samples but not in
cord samples (< 0.1 ng/mL). PFOA may pose
a developmental risk to children at concentra-
tions already found in the blood of women
and children, according to a U.S. EPA prelim-
inary risk assessment released in April 2003
(Renner 2003). Kannan et al. (2002a) meas-
ured FOCs, including PFOA, in bird livers
collected from Japan and South Korea and
found that the highest concentration of PFOA
in the samples was 21 ng/g wet weight. PFOA
has been found in environmental samples
(Giesy and Kannan 2001; Kannan et al.
2002b). However, we do not know how peo-
ple are exposed to PFOA according to a
nonoccupational exposure assessment study.
The occupational exposure levels of PFOA in
humans are 1,780 ng/mL with a range of
40–10,060 ng/mL (Olsen et al. 2003a), and
899 ng/mL with a range of 722–1,120 ng/mL
(Olsen et al. 2003c). By contrast, nonoccupa-
tional exposure to PFOA was found to be at
trace levels (range of < 0.5–4.1 ng/mL, 15 of
21) in our other study (Okada et al. 2003).
Therefore, we surmise that fetal exposure to
PFOA is at trace levels. Recently, the dissocia-
tion constants for PFOA binding to human
serum albumin (HSA) and the number of
PFOA binding sites on HSA were determined
(Han et al. 2003). At the same time, Han
et al. (2003) predicted that PFOA bound to
maternal blood protein may not be able to
cross the placental barrier. The reasons for the
trace levels of PFOA in fetal blood samples are
nonoccupational exposure and the binding of
PFOA to maternal blood protein.
Children’s Health | Inoue et al.
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Figure 1. PFOS concentrations in maternal and cord
blood samples (r2 = 0.8759; y = 0.3332x–0.0877).
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Figure 2. Maternal age (A) and BMI (B) plotted
against PFOS concentration in maternal blood
samples (n = 15).
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Figure 3. Infants’ sex (A) and birth weight (B) plotted
against PFOS concentration in cord blood samples
(n = 15). Error bars indicate mean ± SD.
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Figure 4. Infants’ thyroid hormones levels (TSH and
free T4) plotted against PFOS concentration in cord
blood samples (n = 15).
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Like polychlorinated biphenyls, organo-
chlorine pesticides, and polybrominated
diphenyl ethers, PFOS may be able to cross the
placental barrier to enter fetal circulation
(Covaci et al. 2002; DeKoning and Karmaus
2000; Mazdai et al. 2003; Sala et al. 2001;
Waliszewski et al. 2000). Our data suggest that
the slope is approximately 0.33 (Figure 1),
indicating that PFOS does not pass into
the fetal circulation completely; that is, there
does seem to be a barrier effect. In contrast to
PFOS, however, PFOA and PFOSA cannot
cross the placental barrier to enter fetal circula-
tion. PFOS is known to exhibit developmental
toxicity and postnatal effects, as has been
demonstrated in experimental animal studies
(Lau et al. 2003; Thibodeaux et al. 2003). In
those studies, exposure to PFOS during preg-
nancy led to signiﬁcant physiologic alterations
that indicate maternal toxicity. In addition,
these results indicate that in utero exposure to
PFOS severely compromises postnatal survival
of neonatal rats and mice and causes delays in
growth and development accompanied by
hypothyroxinemia in the surviving rat pups.
However, little research has been conducted on
the effects of PFOS on the human fetus,
including epidemiologic, analytic, and toxico-
logic studies. It is necessary to investigate PFOS
effects on thyroid hormone levels in a large
number of fetuses. PFOS affects the estrous
cycle and functions as an endocrine disruptor
(Austin et al. 2003). Thyroid hormones play an
important role in brain development, and deﬁ-
ciencies in T4 are known to cause mental delay
in humans. In the present study, there was no
apparent association between fetal PFOS con-
centration and thyroid hormones; however, the
sample size may have been too small to detect
such a relationship in a human population.
Large-scale follow-up studies are necessary to
assess the adverse effects of exposure to PFOS
and related compounds on fetal development.
Further exposure assessment studies of PFOS in
the susceptible population during pregnancy
are needed to determine whether maternal
exposure to PFOS can lead to adverse effects on
the endocrine system in offspring. The descrip-
tion of a large-scale fetal population and the
effects of PFOS on the endocrine system will be
detailed in a forthcoming paper.
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